Lingkang Pharmaceutical (603669.SH) released its first three quarters performance, with a net profit attributable to shareholders of 31.83 million yuan, turning losses into profits year-on-year.

Zhitong Finance APP News, Lingkang Pharmaceutical (603669.SH) disclosed its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 360 million yuan, a year-on-year increase of 27.79%; net profit attributable to shareholders of the listed company was 31.83 million yuan, turning from loss to profit year-on-year; net profit after deducting non-recurring gains and losses was 23.61 million yuan, turning from loss to profit year-on-year; basic earnings per share were 0.0441 yuan.